Invention:
This technology features the use of a transcription inhibitor combined with a DNA damaging agent to induce tumor cell death for tumors that have FET-fused oncogenes, such as cells and tumors associated with Ewing's sarcoma and fibromyxoid Iposarcoma. This combination therapy targets members of the FET protein family that are translocated to form fusion oncogenes. This presents an opportunity to use FET-protein fusions as a means of identifying and treating cancer. Combined treatment of Ewing's sarcoma with a transcription inhibitor increases cellular sensitivity to DNA damage agents. Tumors showing translocation of these FET proteins would also be susceptible to treatment with transcription inhibitors.
Background:
It is estimated that 12,390 people will be diagnosed with a 4,990 will die annually from soft-tissue-sarcoma in the United States. Because current treatment options are invasive and expensive, patients are left with negative side effects and large financial burdens. This technology helps to remedy this tissue by providing a source of relief that is less invasive and burdensome.
Applications:
- Ewing's sarcoma
- Potential to treat other cancer
Advantages:
- Non-invasive and specific means of targeting conditions such as Ewing's sarcoma
- Indicates and sensitizes tumors for more effective treatment
- Limits treatment toxicity effects by lower dose requirements
